Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation

This study evaluates sales revenue earned in the first 5 years for newly marketed brand-name drugs with and without an initial orphan drug designation.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA : the journal of the American Medical Association 2023-05, Vol.329 (18), p.1607-1608
Hauptverfasser:	Tu, S. Sean, Nagar, Sarosh, Kesselheim, Aaron S, Lu, Zhigang, Rome, Benjamin N
Format:	Artikel
Sprache:	eng
Schlagworte:	Commerce - economics Commerce - legislation & jurisprudence Commerce - statistics & numerical data Commerce - trends Drug delivery Drugs Incentives Legislation, Drug - economics Legislation, Drug - statistics & numerical data Letter Letters Marketing - economics Marketing - legislation & jurisprudence Marketing - statistics & numerical data Orphan Drug Production - economics Orphan Drug Production - legislation & jurisprudence Orphan Drug Production - statistics & numerical data Pharmaceutical industry Pharmaceuticals Prescription drugs Prescription Drugs - economics Research Letter Sales Tax credits Taxation United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This study evaluates sales revenue earned in the first 5 years for newly marketed brand-name drugs with and without an initial orphan drug designation.
ISSN:	0098-7484 1538-3598
DOI:	10.1001/jama.2023.3079